QRP Research Sermorelin 10mg
 
Sermorelin, also known as GHRH(1–29) or GRF(1–29), is a synthetic peptide corresponding to the first 29 amino acids of human Growth Hormone-Releasing Hormone (GHRH).
The N-terminal 1–29 region of GHRH contains the key structural elements required for interaction with the Growth Hormone-Releasing Hormone Receptor (GHRH-R). This has made Sermorelin an important experimental compound for investigating GHRH receptor pharmacology, pituitary signalling and regulation of the somatotropic axis.
Sermorelin interacts with GHRH receptors located on anterior pituitary somatotroph cells. Activation of this receptor is associated with intracellular signalling involving adenylyl cyclase, cyclic AMP (cAMP), protein kinase A (PKA) and downstream pathways involved in growth hormone synthesis and secretion.
Unlike GHRP-class research compounds such as GHRP-2 and GHRP-6, which primarily interact with the growth hormone secretagogue receptor (GHS-R), Sermorelin provides a research model for studying the GHRH/GHRH-R pathway.
QRP Research Sermorelin 10mg is supplied as a lyophilised research peptide intended exclusively for controlled laboratory, analytical and scientific investigation.
Key Research Areas
Sermorelin has been investigated experimentally in relation to:
Growth Hormone-Releasing Hormone Receptor (GHRH-R) signalling
GHRH receptor pharmacology
Pituitary somatotroph signalling
Growth hormone synthesis and secretion mechanisms
Hypothalamic-pituitary signalling
cAMP / PKA intracellular signalling
Somatotropic-axis regulation
GH / IGF-1 axis research
Peptide-receptor interactions
GHRH structure-activity relationships
Endocrine and neuroendocrine signalling
Comparison of GHRH and growth hormone secretagogue pathways
A particularly important characteristic of Sermorelin is its structure as the 29-amino-acid N-terminal fragment of human GHRH, providing researchers with a well-characterised model for investigating GHRH receptor activation and downstream signalling.
Its mechanism is distinct from ghrelin-receptor agonists and GHRP-class peptides, making Sermorelin particularly relevant for comparative studies of different pathways involved in experimental growth hormone regulation.
Research findings involving Sermorelin should not be interpreted as evidence of established anti-ageing, muscle-building, performance-enhancing, therapeutic or other clinical effects of this research product.
Product Specification
Compound: Sermorelin
Alternative Names: GHRH(1–29) / GRF(1–29)
Compound Type: Synthetic GHRH-derived peptide
Peptide Length: 29 amino acids
Parent Hormone: Growth Hormone-Releasing Hormone (GHRH)
Primary Research Target: Growth Hormone-Releasing Hormone Receptor (GHRH-R)
Primary Research Pathway: GHRH / GHRH-R / cAMP Signalling
Form: Lyophilised peptide
Quantity: 10mg per vial
Brand: QRP Research
Application: Laboratory and scientific research
Why QRP Research?
QRP Research supplies specialist research materials with an emphasis on quality, consistency and traceability. Products are securely packaged and clearly identified for their intended laboratory application.
Storage
Store in a cool, dry and dark environment, protected from excessive heat, direct light and moisture.
Appropriate laboratory storage procedures should be followed to preserve the stability and integrity of the research material.
Research Use Notice
FOR RESEARCH USE ONLY.
This product is supplied exclusively for laboratory, analytical and scientific research.
NOT for human consumption or administration.
NOT for animal consumption or administration.
NOT a medicine, food supplement or cosmetic product.
NOT intended to diagnose, treat, cure or prevent any disease.
No human dosing or administration instructions are provided.
Intended to be handled only by appropriately qualified researchers or laboratory professionals.
QRP Research Sermorelin 10mg is supplied strictly as a research material for non-clinical laboratory investigation.